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Introduction: Gastric cancer is a heterogeneous disease, whose pathological and clinical patterns have
changed in the last decades. In most western countries, decreases in incidence and mortality and a
proximal migration have been reported. The clinical and pathological trends in an European country with
high prevalence of gastric cancer were reviewed, based on the patients treated at a University Hospital.
Methods: Analysis of a prospective database with 1618 patients who underwent surgery for gastric cancer
in the last 3 decades. The patients were divided in 3 groups according to decades and the cohorts were
analyzed according to demographic, surgical and pathological factors.
Results: The mean age increased from 59.8 to 65.6 years. Antral tumors and intestinal cancer were the
most frequent. The rate of complete resection increased as well as the percentage of total gastrectomies
and D2-type lymphadenectomies.
There was an increase both in early stage carcinomas and in surgically treated Stage-IV carcinomas. The
median overall crude survival almost doubled from 14 to 22 months (p ¼ 0.003), but once stratiﬁed for
stage, only in stage II patients could we observe a signiﬁcant increase in survival time. (29e47 months;
p ¼ 0.047).
Conclusion: The proximal migration described for Western Europe was not observed and the intestinal-
type carcinoma is still the most frequent. We are treating older patients, often with more advanced
disease. In spite of an increasing surgical aggressiveness, the prognosis has only been signiﬁcantly
improved in Stage-II cancers. The prognosis for advanced cancer is still dismal, hence the need for
effective adjuvant treatments.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Despite a global decline over the last decades, gastric cancer is
still the fourth most common malignancy worldwide and the sec-
ond leading cause of death related to malignant disease.1 An
effective decrease in the incidence of gastric adenocarcinoma and a
steady increase in adenocarcinoma of the gastro-esophageal junc-
tion have been reported.2e9 However, there are major regional
differences in the incidence and trend of gastric cancer and the rate
of decline seems to be lower in high-incidence areas.10,11 The sur-
vival rate for patients treated for gastric cancer has not increased in
the last decades,1,12 remaining one of the most lethal solid tumors
with an overall 5-year survival rate of 24.1% in European coun-
tries.13 The aim of the present study is to assess the changes ineda Prof. Hernâni Monteiro,
tugal. Tel.: þ351 917 527 398.
tcabo.pt (G.R. Faria).
ciates Ltd. Published by Elsevier Ltpatterns and survival of gastric cancer, based on the study of pa-
tients treated at a University Hospital in a high-incidence European
region.
2. Methods
We have conducted an analysis of a prospective database collected in a Uni-
versity Hospital since 1980. Patients were divided into 3 cohorts according to de-
cades (Group 1e1980e1989 [n ¼ 326]; Group 2e1990e1999 [n ¼ 420]; Group 3e
2000e2009 [n ¼ 872]) and the groups were analyzed according to demographic,
surgical and pathological factors. All the patients (n ¼ 1618) that underwent surgical
treatment for adenocarcinoma of the stomach or gastro-esophageal junction (GEJ)
were analyzed. Patients not proposed for surgery were excluded from the study. All
the diagnoses were conﬁrmed by histological post-operative exam.
Tumor staging was based on the TNM 1997 classiﬁcation, based on pathological
exam. R0 surgery was considered complete tumor resection with clear histological
margins and early cancer was considered for T1 tumors, irrespective of N staging.14
The statistical analysis was performed in SPSS v16.0. Statistical signiﬁcance was
considered at a p< 0.05 level. The comparison between groups was performed with
ANOVA test for continuous variables and the trended chi-square test for nominal
variables. Survival analysis was performed with the log-rank test applied on
KaplaneMeier curves.d. All rights reserved.
Table 1
Characteristics of patients according to year of diagnosis.
1980e1989
n ¼ 326
1990e1999
n ¼ 420
2000e2009
n ¼ 872
p
Age at surgery 59.8  13.4 63.7  13.8 65.6  12.8 <0.001
Male gender 209 (64.1%) 269 (64.0%) 551 (63.2%) 0.93
Tumor location <0.001
EG junction 31.7% 21.4% 13.4%
Body 15.8% 26.3% 23.5%
Antrum 44.0% 45.0% 55.9%
Extensive 1.4% 2.7% 3.4%
Stump 7.0% 4.6% 3.9%
Table 3
Pathologic characteristics according to year of diagnosis.
1980e1989
n ¼ 326
1990e1999
n ¼ 420
2000e2009
n ¼ 872
p
Stage <0.001
IA 17.7% 11.9% 14.2%
IB 30.0% 19.0% 17.5%
II 20.0% 19.4% 17.5%
IIIA 15.4% 24.5% 16.0%
IIIB 5.4% 5.9% 7.4%
IV 11.5% 19.4% 27.3%
Early cancer 14.5% 14.7% 20.8% 0.040
T (TNM1997) 0.129
T0 1.5% 0% 0.7%
T1 13.8% 14.7% 20.1%
T2 48.7% 45.7% 44.1%
T3 31.8% 31.8% 29.7%
T4 4.1% 7.8% 5.3%
Nþ 57.3% 68.0% 68.1% 0.018
No of invaded lymph
nodes
4.06  7.5 4.98  7.4 6.15  8.5 0.017
Lymphatic invasion 75.8% 84.3% 79.9% 0.081
Venous invasion 38.7% 54.5% 59.7% <0.001
Laurén classiﬁcation <0.001
Intestinal 52.4% 54.3% 44.0%
Diffuse 25.9% 25.6% 21.8%
Unclassiﬁed 21.7% 20.1% 34.2%
Ming classiﬁcation <0.001
Expansive 43.5% 32.9% 22.0%
Inﬁltrative 55.9% 65.0% 73.6%
Unclassiﬁed 0.5% 2.1% 3.0%
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The mean age of patients at the time of surgery (Table 1)
increased along time, from 59.5 to 65.6 years for the patients
treated before 1990 and after 2000 (p < 0.001). Approximately 2/3
of the patients were male, without signiﬁcant changes along time.
We could observe a relative decrease (Table 1) in the number of
carcinomas of the gastro-esophageal junction (35.5%e13.3%) and of
the gastric stump (6.2%e3.9%; p < 0.001). Antral tumors were the
most frequent in all time-periods, increasing from 41.4% to 55.7%.
The rate of resection surgery (Table 2) did not change signiﬁ-
cantly between the 1980’s and the 2000’s (p¼ 0.242), but the actual
rate of complete resection (R0) increased from 51.3% to 81.6%
(p < 0.001), despite treating more advanced tumors.
We could observe an increase in the preference for total gas-
trectomies (in spite of increasing antral tumors) from15.0% to 40.8%
(p < 0.001). Surgical aggressiveness increased along time, with an
increasing rate of D2 type lymphadenectomies from 15.0% to 40.8%
(p< 0.001) and an increase in the number of retrieved lymph nodes
from 15.2 to 25.4 (p < 0.001). The frequency of D2 type lymphade-
nectomies increased both inpatients submitted to total gastrectomy
(52.0%e80.6%) and in distal gastrectomy (31.1%e55.6%). The 30-
days’ mortality did not change signiﬁcantly along time (Table 2).
There was no association between D2 lymphadenectomy and
increased peri-operative mortality and 30-days’ mortality was
signiﬁcantly higher in patients that underwent non-resection sur-
gery (overall 22.7% vs 5.9%; p < 0.001 in all time-periods).
There was an increase both in early stage carcinomas (early
gastric cancer rose from 14.5% in the 1980’s to 20.8% in the 2000’s;
p ¼ 0.04) and in the surgically treated advanced carcinomas (Stage
IV rose from 11.5% to 27.3%; p < 0.001). The tumor progression
along the gastric wall (T) was not signiﬁcantly different along time
(Table 3), but the number of lymph-node positive cancers rose fromTable 2
Characteristics of surgery according to year of diagnosis.
1980e1989
n ¼ 326
1990e1999
n ¼ 420
2000e2009
n ¼ 872
p
Resection surgery 67.2% 63.3% 68.0% 0.242
R0 Surgery 51.3% 54.6% 81.6% <0.001
Total gastrectomy 15.0% 31.6% 40.8% <0.001
D2 Lymphadenectomy 12.6% 36.4% 43.2% <0.001
D2 Lymphadenectomy
Total gastrectomy 52.0% 77.4% 80.6% 0.005
Distal gastrectomy 31.1% 37.3% 55.6% <0.001
No of retrieved
lymph nodes
15.26  9.8 18.66  11.0 25.37  13.6 <0.001
30-day mortality 9.9% 10.8% 12.6% 0.323
Non D2 lymph 11.0% 14.7% 18.2% 0.005
D2 lymph. 2.2% 3.9% 5.3% 0.282
Resection surgery 22.7% 3.3% 6.1% 6.9% 0.135
Non-resection surg 5.9% 22.4% 18.8% 25.1% 0.33157.3% to 68.1%, (p ¼ 0.018). The mean number of invaded lymph
nodes also increased from 4.06 to 6.15 (p ¼ 0.017). The dominant
histological type (Laurén Classiﬁcation) was intestinal adenocarci-
noma, but it decreased from 52.4% to 44.0% (p < 0.001) and the
diffuse-cell type remained fairly constant. As for the Ming classiﬁ-
cation, we could observe a steady increase in inﬁltrative type
cancer (55.9%e73.6%; p < 0.001).
The overall median survival (Table 4) almost doubled from 14 to
22 months, from the 1980’s to the 2000’s (Fig. 1; p ¼ 0.003).
However, we could only observe a signiﬁcant increase in survival
time (18e54months; p¼ 0.047) in stage II patients (Fig. 2). Survival
time was signiﬁcantly increased (p < 0.001) in patients with D2
type lymphadenectomies (42 months median survival vs. 12
months for patients with non-D2 resections), but there were no
signiﬁcant differences in the time-trends for each type of surgery.4. Discussion
Portugal is a high-risk country for gastric cancer, with an inci-
dence of 30e40 per 100.000 men and 15 to 20 per 100.000Table 4
Survival analysis.
1980e1989
n ¼ 326
1990e1999
n ¼ 420
2000e2009
n ¼ 872
p
Median Survival 14 [11.7; 16.3] 20 [14.8; 25.2] 22 [17.8; 26.1] 0.003
Median Survival
Stage I NA NA NA 0.863
Stage II 18 [11.5; 24.5] 45 [21.8; 68.2] 54 [NA] 0.047
Stage III 15 [6.3; 23.7] 18 [11.7; 24.3] 20 [17.1; 22.9] 0.802
Stage IV 11 [6.6; 15.4] 13 [10.7; 15.3] 13 [7.4; 18.6] 0.355
% Survival 5 years 24.8% 33.0% 33.5%
% Survival 5 years
Stage I 64.7% 72.5% 71.0%
Stage II 28.6% 40.7% 47.0%
Stage III 18.8% 24.7% 11.3%
Stage IV 0.0% 13.2% 7.3%
Fig. 1. Crude cumulative survival curve (KaplaneMeier) according to period of diagnosis. (p ¼ 0.003).
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ORIGINAL RESEARCHwomen.15,16 There has been a worldwide decrease in gastric cancer
incidence and mortality, starting in the 1930’s in the USA, but
mortality rates in Portugal have only had a modest reduction.15,16
In this study we present the evolution of surgically treated
gastric cancer in the last 3 decades, in a single institution. As such,Fig. 2. Cumulative survival curve (KaplaneMeier) for patients withwe can’t draw any conclusions regarding gastric cancer incidence
or population-derived estimates of mortality. However, the
changes in the patterns, staging, location, histology and survival
may help us draw a picture about the behavior of this heteroge-
neous disease.stage II disease, according to period of diagnosis. (p ¼ 0.047).
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based observations it is difﬁcult to reach signiﬁcant conclusions
about cancer location and histological types.10 This study is based
on a prospective database and thus the data is accurate and com-
plete. However, as the database has been built during 30 years,
some information presently regarded as important (e.g. H. pylori
infection) is not available for the majority of the patients and was
not used in the analysis.
Over the last 30 years, the patients thatwe have been treating are
getting “older”, with an increase inmean age from60 to 66 years old,
as corroborated by other reports.4,6 According to some authors, the
older age at diagnosis is more concurrent with a lower-incidence of
gastric cancer,17 but in our sample this probably represents both an
aging population and a “lower threshold” for surgery as in the 21st
century, we can offer safer surgery for older patients.
As reported worldwide, there is a male predominance in gastric
cancer, which did not change over time.1,4,12
According to several studies, the number of GEJ and proximal
gastric adenocarcinomas has been increasing, together with a
decrease in carcinomas of the antrum.2e9 However, most of the
studies have been performed in low-risk areas or in Japan. In this
series, we have observed a relative decrease in proximal tumors
and an increase in tumors of the gastric antrum. The relative
decrease in the number of GEJ carcinomas probably does not
represent a true decrease in its incidence, but rather an increase in
the number of patients treated for gastric cancer at our institution
and the development of surgical care at other institutions allowing
them to treat more proximal tumors. We have also observed a
continuous decrease in cancer of the gastric stump, which might be
related to the decreasing number of sub-total gastrectomies per-
formed for peptic ulcer disease.
The rate of surgical resection remained fairly constant over time.
However we are now treating more patients with more advanced
disease. With the increasing preference for total gastrectomies and
D2 type lymphadenectomy, we observed a signiﬁcant increase in
the rate of R0 resections. Other reports have previously conﬁrmed
this increase in complete resection rates5,6,18,19 and a trend toward
preference for total gastrectomy,6,8 especially in centers with high
volume and low morbidity. The number of lymph nodes retrieved
from the surgical specimen increased consistently even in patients
that underwent distal gastrectomy, allowing a more accurate
staging.
The 30-daymortality rate represents not only patients who have
died from post-operative complications, but also patients with
advanced stage disease. We could observe that D2 type lympha-
denectomy was related to a lower 30-day mortality. This probably
represents a shorter survival (and increased mortality) in patients
with non-curative resections or non-resectional surgeries. The
overall mortality rates are in line with reports in the literature8,20
and, in contrast with other studies,21,22 we did not ﬁnd an associ-
ation between D2 type resection and increased morbidity or peri-
operative mortality.
In spite of the advances in Medicine, with the exception of
systematic screening programs, gastric cancer stage at the time of
diagnosis remains very advanced.17 A study in the USA23 concluded
that two-thirds of the patients had stage III or IV disease at the time
of diagnosis and a study from the Netherlands observed that, from
the early 90’s to mid 00’s, there was an increase in stage IV disease
from 31% to 40%.12 In this report, we have witnessed an increase
both in early gastric cancer (14.5%e20.8%) and in stage IV cancer.
This may be due in some part to the increased awareness and
screening in high-risk patients and, on the other hand, to the
increased aggressiveness and treatment at surgical units of patients
with advanced disease. Regarding the proportion of early gastric
cancer, we report an increasing percentage (from 14.5 to 20.8% inthe latter years) of patients presentingwith early cancer, in contrast
to a proportion of 40e60% in Japan, 16e20% in Germany, 14% in
Poland, 9% in USA and 1% in the UK.8,24e26
As for the other examined histological characteristics, only in
the number of invaded lymph nodes and venous invasion could we
see a signiﬁcant change with time, which might both be due to
more thorough pathological examination or, as reported before,
associated with increasing age.27 As for the histological type, we
have seen a stable preponderance of intestinal type (Laurén clas-
siﬁcation), but a signiﬁcant increase in unclassiﬁed type carci-
nomas. In contrast with other reports,4,18,28 the relative frequency
of isolated cell carcinomas did not increase over time. However, the
inﬁltrative type cancers (according to Ming classiﬁcation) have
seen a steady increase (56%e74%).
The survival results were similar to those in Japan20,29 and in
recent European studies30e32 contrasting with older results in Eu-
ropean countries21,33 and the USA.34 We report a crude increase in
survival in patients with D2 lymphadenectomy (42 vs 12 months
median survival). However, this observation might have a selection
bias, as with the systematic use of D2 lymphadenectomy at our
institution, the patients who underwent non-extended resections
were mainly patients with non-curative resections or very high
surgical risk.
We have observed a small but steady increase in overall survival,
from 24.8% to 33.5% at 5-years. This increasing survival has been
reported before and seems to be due to improvements in operative
procedures and postoperative management.6,20,35 Although the
crude 5-year survival increased only about 8%, the 1980’s survival in
our series already matched the current overall 5-year survival in
Europe for gastric cancer (25%).1,12 This might mean that we are at a
plateau for the results of surgical treatment and further improve-
ments in survival might arise from earlier detection or more
effective adjuvant treatment. When stratiﬁed by staging, we could
only observe a signiﬁcant increase in survival for patients with
Stage II cancer (median survival increased from 18 to 54 months).
These patients clearly beneﬁted from increasingly aggressive sur-
gical treatment. Survival in patients with early gastric cancer
remained high, but patients with stage III or IV gastric cancer still
have a dismal prognosis. This probably translates the lack of
effective adjuvant treatment5,7,12 and the need for further research
in the biology of gastric cancer.
5. Conclusion
Surgical aggressiveness has signiﬁcantly increased during the
last 3 decades and the prognosis signiﬁcantly increased in stage II
cancers. We are treating older patients, often with more advanced
disease. We cannot conﬁrm the proximal migration of gastric
cancer and the intestinal type carcinoma is still the most frequent.
There is still a dismal prognosis for advanced stage gastric cancer
and a need for effective adjuvant treatments.
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